Highest-materiality recent filing
TOI secures $75M OrbiMed term loan, repays $86M Deerfield convertible note
$75M term loan from OrbiMed, matures 2031, interest at SOFR+5.75% (floor 3%).
Oncology Institute patient data accessed in Vendor cybersecurity incident; operations sustained
On May 20, 2026, Kroll notified TOI that its Vendor detected unauthorized access to TOI patient data systems.
TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M
Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.
Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M
Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).
2026 revenue guidance $630M-$650M, ~28% growth from 2025 midpoint.
TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance
Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.
TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance
Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.
TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance
Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.
TOI shareholders approve reverse stock split up to 1:40; re-elect all 8 directors
Reverse stock split approved at ratio between 1:5 and 1:40, board discretion within one year.
The Oncology Institute closes ~$16.4M private placement and $4.1M note exchange
Private placement of 12.0M shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.
The Oncology Institute raises $16.5M via private placement and exchanges $4.1M notes
Gross proceeds of ~$16.5M from issuing 12.0M common shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.
TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M
Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.
TOI amends Deerfield credit agreement, removes $40M cash covenant, pays down $20M notes
Deerfield waived restrictions on equity issuance and removed the $40M minimum cash covenant.
Nasdaq grants TOI additional 180 days to meet $1 minimum bid price through June 16, 2025
Received Second Nasdaq Bid Price Letter on Dec 19, 2024 granting extension to June 16, 2025.
TOI Q3 revenue up 22% to $99.9M; net loss narrows to $16.1M, adjusted EBITDA -$8.2M
Revenue $99.9M (+21.8% YoY), driven by dispensary revenue surge of 79.9%.
TOI CFO Mihir Shah resigns; Rob Carter promoted to CFO effective Oct 14
CFO Mihir Shah resigns effective October 14, 2024, to pursue other opportunities; departure not related to operations or accounting policies.
TOI reports Q2 revenue $99M (+23% YoY), net loss $15.5M; exploring strategic alternatives
Q2 revenue $99M (+22.9% YoY); net loss $15.5M vs $16.9M prior year; EPS ($0.17).
The Oncology Institute receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days
Nasdaq notice on June 20, 2024 for non-compliance with minimum bid price rule 5550(a)(2).
Oncology Institute Q1 revenue up 24% to $95M; net loss narrows to $19.9M
Revenue of $95M (+24.2% YoY); net loss $19.9M vs $30.0M loss in prior year.
TOI reports Q4 revenue $86M (+20.1% YoY), net loss widens to $18.8M
Q4 2023 revenue $86M (+20.1% YoY); gross profit $14M (-8.0% YoY).
TOI reports Q3 revenue $82M (+26% YoY), net loss widens to $17.4M from $2.7M
Revenue $82M (+26% YoY); gross profit $16M (+23% YoY); gross margin 19.5% (down from 20.0%).
TOI Q2 revenue up 32% to $80M, net loss widens to $16.9M, reaffirms FY 2023 guidance
Revenue of $80M (+32% YoY); gross profit $15M (+36%); gross margin 18.8% vs 18.3%.
Oncology Institute authorizes up to 5M share buyback at ≤$0.75; obtains lender consent
Board approved repurchase of up to 5M shares of common stock at price not exceeding $0.75 per share.
The Oncology Institute names Daniel Virnich as CEO, Brad Hively becomes Vice Chairman
Brad Hively steps down as CEO effective June 30, 2023, becomes Vice Chairman.
Oncology Institute Q1 revenue $76M (+38% YoY) but net loss $30M, EBITDA loss widens
Revenue of $76M, up 38.1% YoY; gross profit $14M (18.5% margin, down from 22.3%).
Oncology Institute receives Nasdaq delisting warning over bid price below $1.00
Nasdaq notified TOI on Apr 25, 2023 of non-compliance with minimum bid price rule (5450(a)(2)).
On May 2, 2025, Jeremy Castle provided notice of his resignation as Chief Operating Officer of The Oncology Institute, Inc. (the “Company”), effective as of May 30, 2025.
On November 8, 2024, Maeve O’Meara notified the Board of Directors of The Oncology Institute, Inc. (the “Company”) of her intention to resign as a director of the Company for personal reasons, effective as of January 1, 2025 (the “Effective Date”).
On September 20, 2024, the Company appointed Robert Carter to replace Mr. Shah as the Company’s Chief Financial Officer, with effect on October 14, 2024.
On September 19, 2024, Mihir Shah, the Chief Financial Officer, principal financial officer, and principal accounting officer of The Oncology Institute, Inc. (the “Company”), delivered a notice of resignation effective as of October 14, 2024.
On September 5, 2023, The Oncology Institute, Inc., a Delaware corporation (the “Company”), appointed Jeremy N. Castle to replace Matthew Miller, MD as the Company’s Chief Operations Officer.
Dr. Miller’s separation from the Company was effective June 16, 2023, as previously disclosed in that certain Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2023.
On August 31, 2023, Ravi Sarin, a member of the Board of Directors (the “Board”) of The Oncology Institute, Inc. (the “Company”), resigned effective immediately as a director of the Board, including any positions held as a member of any committee of the Board.
Brad Hively will transition from his role as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”) to Vice Chair of the Board of Directors of the Company.
the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023
Additionally, the Board appointed Mr. Hively to serve as Vice Chair of the Board at the Effective Time
On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).
Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer
Max materiality 0.75 · Median 0.60 · Most common event earnings